NCT02202785 (Clinical Trial/ Indusatumab vedotin / MLN0264)

Study Title
A Study of MLN0264 in Patients With Pancreatic Cancer (NCT02202785)

Trial Description
The purpose of this study is to assess the efficacy, safety and tolerability of MLN0264 (Indusatumab vedotin) in patients with advanced or metastatic guanylyl cyclase C (GCC)-positive adenocarcinoma of the pancreas.

This trial is sponsored by  Millennium Pharmaceuticals [1]

Study Data

  • Condition: Pancreatic Adenocarcinoma
  • Interventions:
    • Drugs used in this trial
      • MLN0264 (Indusatumab vedotin)
  • Phase: II
  • Estimated Enrollment: 81
  • Start: July 2014
  • Estimated Completion: May 2018
  • Last verified: July 2015

Study Schematic 

NCT02202785 (Clinical Trial/ Indusatumab vedotin / MLN0264)

Click here to Return to Drug map

Last Editorial review: July 17, 2016
Information based on (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.